• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Conference on Drug Design and Discovery Technologies >DESIGN,SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-PHENYLISOXAZOLO5,4-DPYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS
【24h】

DESIGN,SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-PHENYLISOXAZOLO5,4-DPYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS

机译：3-苯基异恶唑的设计，合成和生物学评价5,4-D嘧啶衍生物作为抗癌剂

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cancer is the leading cause of the death since last few decades leading to the death of millions of people worldwide.Cancer is a generic term for a large group of diseases characterized by the growth of abnormal cells beyond their usual boundaries that can then invade adjoining parts of the body and/or spread to other organs.Also as the medication available is leading to the resistance,thus the continuous supply of new and novel anticancer drugs is the demand of the current situation.Derivatizing the existing anticancer drugs is an important strategy for the development of new anticancer agents.Lapatinib is 4-anilinoquinazoline derivative a dual tyrosine kinase inhibitor,acts by disrupting the epidermal growth factor receptor and HER2/neu pathways.Many derivatives of the lapatinib were previously reported by modification on quinazoline ring such as furanopyrimidine1 thiophenopyrimidine2 were found to be promising anticancer agents.Many isoxazole and isoxazolines derivatives have been reported for their anticancer potential3-5,but the fused ring of isoxazole and pyrimidine is not yet explored for anticancer potential.
机译：癌症是死亡的主要原因，自从过去几十年以来导致全球数百万人死亡。癌商是一大群疾病的常规术语，其特征在于超出其通常界限的异常细胞的生长，然后可以入侵毗邻毗邻的零件身体和/或传播到其他器官。当可用药物导致抵抗力时，即抗抗癌的连续供应是目前情况的需求。扩展现有的抗癌药物是一个重要的策略新的抗癌剂的发展是4- anilinoquinazoline衍生物的双酪氨酸激酶抑制剂，通过破坏表皮生长因子受体和Her2 / Neu途径。先前通过对喹唑啉环的改性来报道Lapatinib的Many衍生物，例如呋喃哌啶啉酮庚酮蛋白2被发现是有前途的抗癌剂.many异恶唑和异恶唑啉衍生物已经是r出于抗癌潜力3-5，但尚未探索抗癌潜力的异恶唑和嘧啶的融合环。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号